Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual...
May 15 2020 - 5:00AM
- Affimed researchers served as co-authors on an abstract for
RO7297089 with scientific collaborators from Genentech, a member of
the Roche Group
- Affimed will host a live teleconference at 8am Eastern to
discuss the abstracts and recent corporate developments
Heidelberg, Germany, May 15, 2020 – Affimed
N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer, today announced that data from two studies investigating
innate cell engagers developed from its fit-for-purpose ROCK®
platform have been accepted for e-poster presentations at the
American Association for Cancer Research (AACR) Virtual Annual
Meeting II being held on June 22-24, 2020. Affimed researchers
served as authors on abstract #5659 and co-authors on abstract
#6987 with scientific collaborators from Genentech, a member of the
Roche Group, on the respective abstracts that include the
following:
Title: AFM24, a bispecific
EGFR/CD16A Innate Cell Engager with the potential to overcome
resistance to current targeted treatments for EGFR-positive
malignancies
Abstract: 5659
Authors: Uwe Reusch, Michael
Damrat, Susanne Wingert, Stefan H.J. Knackmuss, Thomas Mueller,
Ivica Fucek, Ute Schniegler-Mattox, Kristina Ellwanger, Torsten
Haneke, Andras Strassz, Wolfgang Fischer, Erich Rajkovic, Michael
Tesar. Affimed GmbH, Heidelberg, Germany
Poster Release: The e-poster
website will be launched on June 22, 2020. All e-posters will be
available for browsing on this date.
Title: Preclinical pharmacology
and safety of RO7297089, a novel anti-BCMA/CD16a bispecific
antibody for the treatment of multiple myeloma
Abstract: 6987
Authors: Satoko
Kakiuchi-Kiyota, Melissa Schutten, Adeyemi O. Adedeji, Hao Cai,
Robert Hendricks, Luna Liu, Sivan Cohen, Aaron Fullerton, Nicholas
Corr, Lanlan Yu, Denise de Almeida-Nagata, Shelly Zhong, Michael
Dillon, Christoph Spiess, Steve Leong, Bing Zheng. Genentech Inc.;
Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Thorsten Ross.
Affimed; Andy Polson, Ayse Meric Ovacik. Genentech Inc.
Poster Release: The e-poster
website will be launched on June 22, 2020. All e-posters will be
available for browsing on this date.
More details about the programs for the AACR
Virtual Annual Meeting II are available online at www.aacr.org.
Conference Call Information
Affimed will host a live teleconference today,
Friday May 15th at 8am Eastern to discuss the abstracts and recent
corporate developments. The teleconference details will be
available in the “Webcasts” section on the “Investors” page of the
Affimed website at https://www.affimed.com/investors/webcasts_cp/,
and a replay of the teleconference will be accessible at the same
link for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The company is developing single and
combination therapies to treat hematologic and solid tumors. The
company’s initial clinical program, AFM13 for CD30-positive
lymphomas, is currently enrolling patients for a
registration-directed study in relapsed/refractory peripheral T
cell lymphoma. For more information, please visit
www.affimed.com.
Investor Contact
Solebury Trout, Thomas HoffmannPhone:
646-378-2931Email: thoffmann@troutgroup.com or IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024
